Pfizer (PFE) revenue breakdown
By segment, Biopharma is the largest at 98% of fiscal 2023 revenue, growing 11% a year over 4 years.
By region, U.S. is the largest at 59% of fiscal 2025 revenue, growing 9% a year over 7 years.
Revenue by segment
Fiscal years, as Pfizer reports them in its 10-K filings; fiscal 2023 total $58.5B.
| Segments | 2019 | 2020 | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|---|---|
| Biopharma | $38.0B | $40.7B | $79.6B | $99.0B | $57.2B | 98% |
| Business Innovation Segment | — | $926M | $1.7B | $1.3B | $1.3B | 2% |
Revenue by region
Fiscal years, as Pfizer reports them in its 10-K filings; fiscal 2025 total $62.6B.
| Regions | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| U.S. | $20.1B | $20.3B | $21.5B | $29.7B | $43.3B | $28.1B | $38.7B | $37.1B | 59% |
| Developed Markets | — | — | — | — | $40.5B | $20.9B | $16.1B | $16.2B | 26% |
| Emerging Markets | $8.6B | $8.8B | $8.4B | $20.7B | $17.3B | $10.5B | $8.9B | $9.3B | 15% |
| Developed Europe | $8.0B | $7.7B | $7.8B | $18.3B | — | — | — | — | — |
| Developed Rest of World | $4.1B | $4.0B | $4.0B | $12.5B | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PFE.
Open PFE in InvestinglyQuestions
Where does Pfizer make its money?
In fiscal 2023, by segment: Biopharma $57.2B, Business Innovation Segment $1.3B.
From Pfizer's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.